Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22748
Title: Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease.
Austin Authors: Amadoru, Sanka ;Doré, Vincent ;McLean, Catriona A;Hinton, Fairlie;Shepherd, Claire E;Halliday, Glenda M;Leyton, Cristian E;Yates, Paul A ;Hodges, John R;Masters, Colin L ;Villemagne, Victor L ;Rowe, Christopher C 
Affiliation: CSIRO Health and Biosecurity, Parkville, Victoria, 3052, Australia
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
Sydney Brain Bank, Neuroscience Research Australia and Faculty of Medicine, University of NSW, Sydney, Australia
Victorian Brain Bank, The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia
The Brain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
Issue Date: 4-Mar-2020
Date: 2020-03-04
Publication information: Alzheimer's research & therapy 2020; 12(1): 22
Abstract: The Centiloid scale was developed to standardise the results of beta-amyloid (Aβ) PET. We aimed to determine the Centiloid unit (CL) thresholds for CERAD sparse and moderate-density neuritic plaques, Alzheimer's disease neuropathologic change (ADNC) score of intermediate or high probability of Alzheimer's Disease (AD), final clinicopathological diagnosis of AD, and expert visual read of a positive Aβ PET scan. Aβ PET results in CL for 49 subjects were compared with post-mortem findings, visual read, and final clinicopathological diagnosis. The Youden Index was used to determine the optimal CL thresholds from receiver operator characteristic (ROC) curves. A threshold of 20.1 CL (21.3 CL when corrected for time to death, AUC 0.97) yielded highest accuracy in detecting moderate or frequent plaque density while < 10 CL was optimal for excluding neuritic plaque. The threshold for ADNC intermediate or high likelihood AD was 49.4 CL (AUC 0.98). Those cases with a final clinicopathological diagnosis of AD yielded a median CL result of 87.7 (IQR ± 42.2) with 94% > 45 CL. Positive visual read agreed highly with results > 26 CL. Centiloid values < 10 accurately reflected the absence of any neuritic plaque and > 20 CL indicated the presence of at least moderate plaque density, but approximately 50 CL or more best confirmed both neuropathological and clinicopathological diagnosis of Alzheimer's disease.
URI: https://ahro.austin.org.au/austinjspui/handle/1/22748
DOI: 10.1186/s13195-020-00587-5
ORCID: 0000-0002-0522-6143
0000-0002-8051-0558
0000-0002-9259-8411
0000-0002-0399-3218
0000-0003-0422-8398
0000-0002-8236-6561
0000-0001-9317-0145
0000-0003-3072-7940
0000-0002-5832-9875
0000-0003-3910-2453
Journal: Alzheimer's research & therapy
PubMed URL: 32131891
Type: Journal Article
Subjects: Alzheimer’s disease
Amyloid imaging
Centiloids
Neuropathology
Positron emission tomography
Appears in Collections:Journal articles

Show full item record

Page view(s)

44
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.